Clinical trials: Lower Urinary Tract Symptoms
Urinary Bladder, Overactive
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.
- Trial name
- CAPRICORN (NCT00912964)
- Testing
- Mirabegron
- Where
- 151 sites in United States, Canada and 9 more
- Volunteers
- 2,030 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Reproducibility Study of Over Active Bladder Symptom Score [OABSS]
The purpose of this study is to evaluate the reproducibility of over active bladder symptom score (OABSS) in Asian countries.
- Trial name
- RESORT (NCT00901251)
- Where
- 5 sites in China
- Volunteers
- 50 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.
Objective of this study was confirmation on non-inferiority and validation of similar safety profile of new anti-muscarinic medicinal product Uritos® (Imidafenacin) in comparison with other product from m-cholinergic antagonists…
- Trial name
- NCT03575702
- Testing
- Uritos®, Urotol®
- Where
- 11 sites in Russia
- Volunteers
- 300 people
- Sponsor
- R-Pharm
Urinary Bladder, Overactive
A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients
The study is intended to test the safety, tolerability, and efficacy of long-term treatment with YM178 in patients with overactive bladder symptoms.
- Trial name
- NCT00840645
- Testing
- YM178
- Where
- 2 sites in Japan
- Volunteers
- 204 people
- Sponsor
- Astellas Pharma Inc
Urinary Incontinence, Urge Incontinence
UCon Treatment of Overactive Bladder (OAB) in Males
UCon is a medical device for treatment of the symptoms of OAB and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder musculature e.g., suppress undesired…
- Conditions
- Urinary Incontinence, Urge Incontinence, Nocturia, Urinary Frequency More Than Once at Night
- Trial name
- NCT05874375
- Testing
- Urge stimulation, Time limited stimulation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- InnoCon Medical
Urinary Incontinence
Clinical Study of External Electrical Stimulation for Male Incontinence
The purpose of this research is to evaluate the effectiveness of the Elidah neuromuscular stimulation treatment to reduce incontinence in men post-prostatectomy.
- Trial name
- NCT06620419
- Testing
- Perineal-applied electrical stimulation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Elidah, Inc.
Urinary Bladder, Overactive
The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose of warfarin (25 mg) in…
- Trial name
- NCT00914667
- Testing
- warfarin, Warfarin plus Fesoterodine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Benign Prostatic Hyperplasia
Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)
This clinical study is designed to evaluate the efficacy and safety of silodosin in a 12 week treatment of patients with severe urinary disorders associated with benign prostatic hyperplasia (BPH).
- Trial name
- STRONG (NCT01259531)
- Testing
- Silodosin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- JW Pharmaceutical
Interstitial Cystitis
Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to determine the safety and pharmacokinetics of TTI-1612 in women with interstitial cystitis/bladder pain syndrome.
- Trial name
- NCT01559961
- Testing
- TTI-1612
- Where
- 4 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Trillium Therapeutics Inc.
Stress Urinary Incontinence
A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence
The purpose of this study is to determine whether EG017 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.
- Trial name
- NCT05674045
- Testing
- EG017 3mg, EG017 6mg
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Overactive Bladder
A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together
- Trial name
- NCT00501267
- Testing
- solabegron and oxybutynin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects, Overactive Bladder
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of different formulations of orally administered solabegron in healthy male subjects.
- Trial name
- NCT02938507
- Testing
- Formulation 1 solabegron, Formulation 2 solabegron
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Velicept Therapeutics, Inc.
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
This is a phase 2 study to evaluate the safety and effectiveness of light-activated talaporfin sodium in patients with LUTS due to benign prostatic hyperplasia (BPH).
- Trial name
- NCT00918034
- Testing
- talaporfin sodium, Transurethral illumination with light emitting diodes, Placement
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 21 people
- Sponsor
- Light Sciences Oncology
Urge Incontinence
Efficacy of Surface Electrical Stimulation for Urge Urinary Incontinence in Women
The purpose of this research is to evaluate the effectiveness of the ELITONE-UUI electrical muscle stimulation device on treating urge incontinence.
- Trial name
- NCT04752709
- Testing
- ELITONE UUI
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Elidah, Inc.
Stress Urinary Incontinence
A Pilot Clinical Study of the Efficacy and Safety of a Disposable Intravaginal Device for Stress Urinary Incontinence
This pilot study will evaluate the efficacy of the pessary (disposable intra-vaginal device) by reduction in urine leakage in women with stress urinary incontinence (SUI).
- Trial name
- NCT01762345
- Testing
- pessary (disposable intra-vaginal device)
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Procter and Gamble
Urinary Incontinence, Intrinsic Sphincter Deficiency
Injectable Bulking Agent Needle Guide
The purpose of this study is to evaluate the use of the Needle Guide as an assist in properly guiding an injection needle into the appropriate tissue plane during an injectable bulking agent procedure in women using a FDA…
- Trial name
- NG (NCT00763711)
- Testing
- Needle Guided Periurethral Injection
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Carbon Medical Technologies
Urge Incontinence
Protect Chronic Tibial Nerve Stimulator (CTNS) System
30 patient Study. All patients implanted with StimGuard Protect System. Patient followed out to 90 days.
- Trial name
- NCT02781636
- Testing
- Device: StimGuard Protect System
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Uro Medical Corporation
Urinary Urge Incontinence
Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System
Single-arm study conducted in participants for the treatment of urinary urge incontinence in patients who have failed, could not tolerate, or were not a candidate for more conservative treatments.
- Trial name
- NCT07247136
- Testing
- Neuspera Implantable Sacral Neuromodulation System
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Neuspera Medical, Inc.
Overactive Bladder
Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB
The primary purpose of this study is to assess the efficacy and safety of THVD-201(Combination of tolterodine and pilocarpine) in patients with Overactive bladder during the period of treatment, 12 weeks.
- Trial name
- NCT02485067
- Testing
- THVD-201, Detrusitol 2mg tablet
- Where
- 16 sites in South Korea
- Volunteers
- 384 people
- Sponsor
- SK Chemicals Co., Ltd.
Urinary Incontinence
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA (botulinum toxin Type A; BOTOX®) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in participants who successfully…
- Trial name
- NCT01852058
- Testing
- OnabotulinumtoxinA
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 95 people
- Sponsor
- Allergan